New trial
Phase III Trial: Pafolacianine for Localization of Pediatric Extracranial Solid Tumors
- Trial ID
- NCT06915727 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Published in
- New in Oncology - May 14, 2025
Mayo Clinic is evaluating pafolacianine—an IV-administered, folate receptor-targeted fluorescent imaging agent used with near infrared (NIR) imaging—to enhance the identification of cancerous lesions during standard surgery in children and adolescents with primary or metastatic solid tumors.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings